Nitric oxide synthase in retinal vascular diseases

Studies on Retinal and Choroidal Disorders

Volumn , Issue , 2012, Pages 529-544

  Leal, Ermelindo C ^a   Ambrósio, António F ^a   Cunha Vaz, José ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926253640     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-606-7_26     Document Type: Chapter

References (110)

1. Yu DY, Cringle SJ (2001) Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retin Eye Res 20:175-208.
2. Gruetter CA, Barry BK, McNamara DB et al (1979) Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 5:211-224.
3. Abu El-Asrar AM, Desmet S, Meersschaert A et al (2001) Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 132:551-556.
4. Ando A, Yang A, Mori K et al (2002) Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol 191:116-124.
5. Shareef S, Sawada A, Neufeld AH (1999) Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure. Invest Ophthalmol Vis Sci 40:2884-2891.
6. Toda N, Nakanishi-Toda M (2007) Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res 26:205-238.
7. Korhonen R, Lahti A, Kankaanranta H et al (2005) Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 4:471-479.
8. Ricciardolo FL, Nijkamp FP, Folkerts G (2006) Nitric oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease. Curr Drug Targets 7:721-735.
9. Alderton WK, Cooper CE, Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357:593-615.
10. Ignarro LJ (1990) Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16:477-483.
11. Moncada S (1993) The l -arginine: nitric oxide pathway, cellular transduction and immunological roles. Adv Second Messenger Phosphoprotein Res 28:97-99.
12. Phillips PG, Birnby LM, Narendran A et al (2001) Nitric oxide modulates capillary formation at the endothelial cell-tumor cell interface. Am J Physiol Lung Cell Mol Physiol 281:L278-L290.
13. Sieber CC, Sumanovski LT, Stumm M et al (2001) In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 34:644-650.
14. Prabhakar P, Thatte HS, Goetz RM et al (1998) Receptor-regulated translocation of endothelial nitric-oxide synthase. J Biol Chem 273:27383-27388.
15. Blute TA, Mayer B, Eldred WD (1997) Immunocytochemical and histochemical localization of nitric oxide synthase in the turtle retina. Vis Neurosci 14:717-729.
16. Neufeld AH, Shareef S, Pena J (2000) Cellular localization of neuronal nitric oxide synthase (NOS-1) in the human and rat retina. J Comp Neurol 416:269-275.
17. Cheon EW, Park CH, Kang SS et al (2003) Change in endothelial nitric oxide synthase in the rat retina following transient ischemia. Neuroreport 14:329-333.
18. Ju WK, Gwon JS, Kim KY et al (2001) Up-regulated eNOS protects blood-retinal barrier in the L-arginine treated ischemic rat retina. Neuroreport 12:2405-2409.
19. Tsumamoto Y, Yamashita K, Takumida M et al (2002) In situ localization of nitric oxide synthase and direct evidence of NO production in rat retinal ganglion cells. Brain Res 933:118-129.
20. Goureau O, Regnier-Ricard F, Jonet L et al (1997) Developmental expression of nitric oxide synthase isoform I and III in chick retina. J Neurosci Res 50:104-113.
21. Shin DH, Lim HS, Cho SK et al (2000) Immunocytochemical localization of neuronal and inducible nitric oxide synthase in the retina of zebrafish, Brachydanio rerio. Neurosci Lett 292:220-222.
22. Dawson VL, Dawson TM (1995) Physiological and toxicological actions of nitric oxide in the central nervous system. Adv Pharmacol 34:323-342.
23. Ignarro LJ (1996) Physiology and pathophysiology of nitric oxide. Kidney Int Suppl 55:S2-S5.
24. Szabo C, Thiemermann C (1995) Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol 34:113-153.
25. Cunha-Vaz J (2006) Clínica de la retinopatía diabética. In: Cunha-Vaz J (ed) Retinopatía diabética, 1st edn. Spanish Society of Ophthalmology, Madrid.
26. Wilkinson CP, Ferris FL III, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677-1682.
27. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC (2000) Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. Nitric Oxide 4:590-596.
28. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB (2003) Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162:1995-2004.
29. Kowluru RA (2001) Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 38:179-185.
30. Leal EC, Manivannan A, Hosoya K et al (2007) Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 48:5257-5265.
31. Du Y, Smith MA, Miller CM, Kern TS (2002) Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 80:771-779.
32. Adamis AP (2002) Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 86:363-365.
33. Joussen AM, Poulaki V, Qin W et al (2002) Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 160:501-509.
34. Mamputu JC, Renier G (2004) Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 75:1062-1069.
35. Joussen AM, Poulaki V, Le ML et al (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-1452.
36. Miyamoto K, Ogura Y (1999) Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 14:233-239.
37. Ellis EA, Guberski DL, Hutson B, Grant MB (2002) Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide 6:295-304.
38. Misko TP, Moore WM, Kasten TP et al (1993) Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233:119-125.
39. Edelstein D, Brownlee M (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29.
40. Zheng L, Du Y, Miller C et al (2007) Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50:1987-1996.
41. Cunha-Vaz J, Faria de Abreu JR, Campos AJ (1975) Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 59:649-656.
42. Carmo A, Ramos P, Reis A, Proenca R, Cunha-vaz JG (1998) Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res 67:569-575.
43. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR (1989) Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol 134:231-235.
44. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR (1999) Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 40:689-696.
45. Takeda M, Mori F, Yoshida A et al (2001) Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats. Diabetologia 44:1043-1050.
46. Seven A, Guzel S, Seymen O et al (2003) Nitric oxide synthase inhibition by L-NAME in streptozotocin induced diabetic rats: impacts on oxidative stress. Tohoku J Exp Med 199:205-210.
47. Leal EC, Martins J, Voabil P et al (2010) Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 59:2637-2645.
48. Cunha-Vaz JG, Shakib M, Ashton N (1966) Studies on the permeability of the blood-retinal barrier. I. On the existence, development, and site of a blood-retinal barrier. Br J Ophthalmol 50:441-453.
49. Raviola G (1977) The structural basis of the blood-ocular barriers. Exp Eye Res 25(Suppl):27-63.
50. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA (2006) Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 4:215-227.
51. Miyamoto K, Khosrof S, Bursell SE et al (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836-10841.
52. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM (2007) Leukocytes in diabetic retinopathy. Curr Diabetes Rev 3:3-14.
53. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, Kern TS (2007) Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50:1987-1996.
54. Musashi K, Kiryu J, Miyamoto K et al (2005) Thrombin inhibitor reduces leukocyte-endothelial cell interactions and vascular leakage after scatter laser photocoagulation. Invest Ophthalmol Vis Sci 46:2561-2566.
55. Del Maschio A, Zanetti A, Corada M et al (1996) Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 135:497-510.
56. Bolton SJ, Anthony DC, Perry VH (1998) Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced bloodbrain barrier breakdown in vivo. Neuroscience 86:1245-1257.
57. Xu H, Dawson R, Crane IJ, Liversidge J (2005) Leukocyte diapedesis in vivo induces transient loss of tight junction protein at the blood-retina barrier. Invest Ophthalmol Vis Sci 46:2487-2494.
58. Frank RN (1991) On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 98:586-593.
59. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350:48-58.
60. Du Y, Sarthy VP, Kern TS (2004) Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 287:R735-R741.
61. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424-C1437.
62. Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR (1999) The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res 424:37-49.
63. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288:481-487.
64. Kowluru RA, Koppolu P (2002) Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res 36:993-999.
65. Kowluru RA (2005) Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal 7:1581-1587.
66. Leal EC, Aveleira CA, Castilho AF et al (2009) High glucose and oxidative/nitrosative stress conditions induce apoptosis in retinal endothelial cells by a caspase-independent pathway. Exp Eye Res 88:983-991.
67. Kern TS, Engerman RL (2001) Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 50:1636-1642.
68. Kern TS, Tang J, Mizutani M et al (2000) Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41:3972-3978.
69. Zheng L, Szabo C, Kern TS (2004) Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53:2960-2967.
70. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K (2004) Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci 45:2760-2766.
71. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783-791.
72. Santiago AR, Cristovao AJ, Santos PF, Carvalho CM, Ambrosio AF (2007) High glucose induces caspase-independent cell death in retinal neural cells. Neurobiol Dis 25:464-472.
73. Santiago AR, Rosa SC, Santos PF, Cristovao AJ, Barber AJ, Ambrosio AF (2006) Elevated glucose changes the expression of ionotropic glutamate receptor subunits and impairs calcium homeostasis in retinal neural cells. Invest Ophthalmol Vis Sci 47:4130-4137.
74. Bek T (1994) Transretinal histopathological changes in capillary-free areas of diabetic retinopathy. Acta Ophthalmol (Copenh) 72:409-415.
75. Lieth E, Gardner TW, Barber AJ, Antonetti DA (2000) Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 28:3-8.
76. Bearse MA Jr, Han Y, Schneck ME, Barez S, Jacobsen C, Adams AJ (2004) Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Invest Ophthalmol Vis Sci 45:3259-3265.
77. Greenstein VC, Shapiro A, Zaidi Q, Hood DC (1992) Psychophysical evidence for postreceptoral sensitivity loss in diabetics. Invest Ophthalmol Vis Sci 33:2781-2790.
78. Parisi V, Uccioli L (2001) Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev 17:12-18.
79. Adamis AP, Aiello LP, D'Amato RA (1999) Angiogenesis and ophthalmic disease. Angiogenesis 3:9-14.
80. Madan A, Penn JS (2003) Animal models of oxygen-induced retinopathy. Front Biosci 8:d1030-d1043.
81. Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111.
82. Smith LE (2003) Pathogenesis of retinopathy of prematurity. Semin Neonatol 8:469-473.
83. Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598-614.
84. Hamdi HK, Kenney C (2003) Age-related macular degeneration: a new viewpoint. Front Biosci 8:e305-e314.
85. Hyman L, Neborsky R (2002) Risk factors for age-related macular degeneration: an update. Curr Opin Ophthalmol 13:171-175.
86. Seddon JM, Ajani UA, Sperduto RD et al (1994) Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 272:1413-1420.
87. Hayreh SS, Zimmerman MB, Kimura A, Sanon A (2004) Central retinal artery occlusion. Retinal survival time. Exp Eye Res 78:723-736.
88. Kobayashi M, Kuroiwa T, Shimokawa R, Okeda R, Tokoro T (2000) Nitric oxide synthase expression in ischemic rat retinas. Jpn J Ophthalmol 44:235-244.
89. Sennlaub F, Courtois Y, Goureau O (2001) Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 107:717-725.
90. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L (1995) A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182:1683-1693.
91. Palmer LA, Semenza GL, Stoler MH, Johns RA (1998) Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 274:L212-L219.
92. Bhutto IA, Baba T, Merges C, McLeod DS, Lutty GA (2010) Low nitric oxide synthases (NOSs) in eyes with age-related macular degeneration (AMD). Exp Eye Res 90:155-167.
93. Cherepanoff S, McMenamin P, Gillies MC, Kettle E, Sarks SH (2010) Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol 94:918-925.
94. Hattenbach LO, Falk B, Nurnberger F, Koch FH, Ohrloff C (2002) Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes. Ophthalmologica 216:209-214.
95. Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: role of hypoxiainducible factors. Exp Eye Res 83:473-483.
96. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538-1544.
97. Kroll J, Waltenberger J (1998) VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252:743-746.
98. Ogata N, Yamanaka R, Yamamoto C et al (1998) Expression of vascular endothelial growth factor and its receptor, KDR, following retinal ischemia-reperfusion injury in the rat. Curr Eye Res 17:1087-1096.
99. Stitt AW, Simpson DA, Boocock C, Gardiner TA, Murphy GM, Archer DB (1998) Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intraocular tumours. J Pathol 186:306-312.
100. He T, Ai M, Zhao XH, Xing YQ (2007) Inducible nitric oxide synthase mediates hypoxiainduced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor expression in oxygen-induced retinopathy. Pathobiology 74:336-343.
101. He T, Xing YQ, Zhao XH, Ai M (2007) Interaction between iNOS and COX-2 in hypoxiainduced retinal neovascularization in mice. Arch Med Res 38:807-815.
102. Zhang Q, Zhang J, Guan Y et al (2009) Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 247:919-927.
103. Sennlaub F, Courtois Y, Goureau O (2002) Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. J Neurosci 22:3987-3993.
104. Ghiso N, Rohan RM, Amano S, Garland R, Adamis AP (1999) Suppression of hypoxiaassociated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci 40:1033-1039.
105. Pyriochou A, Vassilakopoulos T, Zhou Z, Papapetropoulos A (2007) cGMP-dependent and -independent angiogenesis-related properties of nitric oxide. Life Sci 81:1549-1554.
106. Mousa SA, Mousa AS (2004) Angiogenesis inhibitors: current & future directions. Curr Pharm Des 10:1-9.
107. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276:43836-43841.
108. Wang X, Wang G, Wang Y (2009) Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 148:883-889.
109. DeNiro M, Al-Halafi A, Al-Mohanna FH, Alsmadi O, Al-Mohanna FA (2010) Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. Mol Pharmacol 77:348-367.
110. Guthrie SM, Curtis LM, Mames RN, Simon GG, Grant MB, Scott EW (2005) The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells. Blood 105:1916-1922.